Legend Biotech Corporation, a global leader in cell therapy based in Somerset, on Monday said it appointed Carlos Santos as its new chief financial officer, effective immediately. Santos will assume the role from Jessie Yeung, who has served as the interim CFO since January 2025.
In his new position, Santos will be responsible for overseeing Legend Biotech’s financial operations, with a focus on strengthening the company’s balance sheet and achieving profitability in 2026. He brings extensive experience from the pharmaceutical and technology sectors, having held leadership positions across the globe.
“His deep financial expertise and operational acumen will be invaluable as we continue to drive the success of CARVYKTI®, our CAR-T cell therapy franchise, and attain companywide profitability in 2026,” Dr. Ying Huang, CEO of Legend Biotech said. Huang also thanked Jessie Yeung for her contributions during her time as interim CFO.
Prior to joining Legend Biotech, Santos served as the CFO for U.S. Oncology at AstraZeneca, where he spent a decade in various financial and leadership roles. He also held CFO positions at Alcon, a division of Novartis, and financial leadership roles at Intel Corporation.
“I am honored to join Legend Biotech at a pivotal moment in its global development and growth,” Santos said. “Legend has established itself as a leader in cell therapy innovation, and I look forward to working alongside this talented executive team to continue building on the Company’s strong foundation.”
